Leah M. Grant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Leah M. Grant has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Holenarasipur R. Vikram
Division of Infectious Diseases and Transplant Center Mayo Clinic Phoenix Arizona USA
3 shared publications Amy Kole
Division of Infectious Diseases,Mayo Clinic,Phoenix,Arizona,USA
1 shared publicationAshley Long
Division of Clinical Informatics & Practice Support, Mayo Clinic Arizona, Phoenix, AZ, USA
1 shared publication- Christopher Saling
Mayo Clinic Arizona
1 shared publication - Dan Ilges
Department of Pharmacy, Mayo Clinic , Phoenix, AZ
1 shared publication - Dora Lam-Himlin
Department of Laboratory Medicine and Pathology,Mayo Clinic,Phoenix,Arizona,USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Infectious Diseases
- Vol. 2026 (1)
Cervical, Mediastinal, and Pericardial Disseminated Coccidioidomycosis: The Importance of Source Control
A 47‐year‐old healthy man developed disseminated coccidioidomycosis involving his mediastinal and cervical lymph nodes that was complicated by pericardial involvement despite continued fluconazole for primary pulmonary infection. Although he subsequently received an aggressive antifungal regimen with voriconazole and liposomal amphotericin B, he did not clinically improve until he underwent major debridement and drainage, highlighting the need for source‐control procedures in some cases of severe disseminated coccidioidomycosis.
- 1 January 2026
- Published by Wiley in Case Reports in Infectious Diseases
- Vol. 2026 (1)
Open AccessCervical, Mediastinal, and Pericardial Disseminated Coccidioidomycosis: The Importance of Source Control
A 47‐year‐old healthy man developed disseminated coccidioidomycosis involving his mediastinal and cervical lymph nodes that was complicated by pericardial involvement despite continued fluconazole for primary pulmonary infection. Although he subsequently received an aggressive antifungal regimen with voriconazole and liposomal amphotericin B, he did not clinically improve until he underwent major debridement and drainage, highlighting the need for source‐control procedures in some cases of severe disseminated coccidioidomycosis.
- Open Access
- 26 November 2024
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 46 (1) , 71-76
Positive impact of a diagnostic stewardship intervention on syndromic panel ordering practices and inappropriate C. difficile treatment
Objective: Multiplex polymerase chain reaction (PCR) panels for stool testing may be used to diagnose Clostridioides difficile, which can circumvent more appropriate targeted C. difficile testing, resulting in treatment of incidentally detected colonization. We sought to reduce C. difficile diagnosis via a gastrointestinal pathogen panel (GIPP).Design: Quasi-experimental, pre/post, retrospective cohort study from January 1, 2022, to January 31, 2024.Setting: Mayo Clinic Arizona—a single academic medical center and associated clinics.Patients: Adult patients receiving C. difficile testing and/or treatment.Methods: Preferred C. difficile testing consisted of glutamate dehydrogenase and toxin antigen immunoassay, followed by toxin gene testing for discrepant results. The GIPP contained 22 targets during the baseline period with C. difficile removed during the postintervention period. Surveys were provided to provider and nursing groups, separately, to identify C. difficile ordering practices and knowledge gaps.Results: At baseline, from January 1, 2022, to January 31, 2023, 2,772 GIPPs were completed for 2,307 unique patients (∼7 per day), primarily for outpatients (1,805 of 2,772, 65%). The most common positive target was C. difficile (517 of 1,018, 51%), which resulted in treatment for C. difficile infection in 94.9% (337 of 355) of cases. Following GIPP C. difficile target removal, GIPP orders decreased from 3.23 to 2.7 per 1,000 patient visits (P < .001). Prescribing of C. difficile treatments decreased in the postintervention period in inpatient and outpatient settings. There were no cases of delayed C. difficile diagnosis during the postintervention period.Conclusions: Removing C. difficile from the GIPP resulted in effective diagnostic and antimicrobial stewardship without resulting in delayed diagnoses.
- 26 November 2024
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 46 (1) , 71-76
Open AccessPositive impact of a diagnostic stewardship intervention on syndromic panel ordering practices and inappropriate C. difficile treatment
Objective: Multiplex polymerase chain reaction (PCR) panels for stool testing may be used to diagnose Clostridioides difficile, which can circumvent more appropriate targeted C. difficile testing, resulting in treatment of incidentally detected colonization. We sought to reduce C. difficile diagnosis via a gastrointestinal pathogen panel (GIPP).Design: Quasi-experimental, pre/post, retrospective cohort study from January 1, 2022, to January 31, 2024.Setting: Mayo Clinic Arizona—a single academic medical center and associated clinics.Patients: Adult patients receiving C. difficile testing and/or treatment.Methods: Preferred C. difficile testing consisted of glutamate dehydrogenase and toxin antigen immunoassay, followed by toxin gene testing for discrepant results. The GIPP contained 22 targets during the baseline period with C. difficile removed during the postintervention period. Surveys were provided to provider and nursing groups, separately, to identify C. difficile ordering practices and knowledge gaps.Results: At baseline, from January 1, 2022, to January 31, 2023, 2,772 GIPPs were completed for 2,307 unique patients (∼7 per day), primarily for outpatients (1,805 of 2,772, 65%). The most common positive target was C. difficile (517 of 1,018, 51%), which resulted in treatment for C. difficile infection in 94.9% (337 of 355) of cases. Following GIPP C. difficile target removal, GIPP orders decreased from 3.23 to 2.7 per 1,000 patient visits (P < .001). Prescribing of C. difficile treatments decreased in the postintervention period in inpatient and outpatient settings. There were no cases of delayed C. difficile diagnosis during the postintervention period.Conclusions: Removing C. difficile from the GIPP resulted in effective diagnostic and antimicrobial stewardship without resulting in delayed diagnoses.
- 13 October 2024
- Published by Wiley in Transplant Infectious Disease
- Vol. 26 (6) , e14394
Brain abscess following solid organ transplantation: A 21‐year retrospective study
Background: Development of brain abscess following solid organ transplantation is associated with significant morbidity and mortality. We undertook a descriptive study to evaluate the etiology, clinical manifestations, diagnosis, management, and outcomes of brain abscess in solid organ transplant (SOT) recipients at three major transplant centers in the United States.Methods: This is a retrospective study of adults with brain abscess following SOT between January 2000 and June 2021 at Mayo Clinic sites in Arizona, Minnesota, and Florida.Results: A total of 39 patients were diagnosed with a brain abscess following SOT. The most common pathogens were Nocardia sp. (24 cases, 61.5% [Nocardia farcinica, 37.5%]), followed by fungi (12 cases, 30.7% [Aspergillus sp., 83.3%]). The majority were kidney transplant recipients (59%). Median time to brain abscess diagnosis was 1.3 years (range, 29 days–12 years) after SOT; 10 of 12 patients (83%) with fungal brain abscess were diagnosed within 1 year after SOT. Twelve patients underwent brain biopsy for diagnosis (25% Nocardia vs. 50% fungal), eight (20.5%) underwent surgical resection of the abscess, and 31 (79.5%) received antimicrobial therapy alone. Median time to brain abscess resolution was 166 days for Nocardia and 356 days for fungal pathogens. Eleven of 39 patients (28.2%) died as a result of their brain abscess, including four of 24 patients (16%) with Nocardia and six of 10 patients (60%) with Aspergillus brain abscess. All‐cause mortality was 43.6%.Conclusion: Brain abscess remains an uncommon infectious complication following SOT. Nocardia and fungi accounted for 92% of pathogens in our cohort. Fungal brain abscess portends a poor prognosis. image
- 13 October 2024
- Published by Wiley in Transplant Infectious Disease
- Vol. 26 (6) , e14394
Brain abscess following solid organ transplantation: A 21‐year retrospective study
Background: Development of brain abscess following solid organ transplantation is associated with significant morbidity and mortality. We undertook a descriptive study to evaluate the etiology, clinical manifestations, diagnosis, management, and outcomes of brain abscess in solid organ transplant (SOT) recipients at three major transplant centers in the United States.Methods: This is a retrospective study of adults with brain abscess following SOT between January 2000 and June 2021 at Mayo Clinic sites in Arizona, Minnesota, and Florida.Results: A total of 39 patients were diagnosed with a brain abscess following SOT. The most common pathogens were Nocardia sp. (24 cases, 61.5% [Nocardia farcinica, 37.5%]), followed by fungi (12 cases, 30.7% [Aspergillus sp., 83.3%]). The majority were kidney transplant recipients (59%). Median time to brain abscess diagnosis was 1.3 years (range, 29 days–12 years) after SOT; 10 of 12 patients (83%) with fungal brain abscess were diagnosed within 1 year after SOT. Twelve patients underwent brain biopsy for diagnosis (25% Nocardia vs. 50% fungal), eight (20.5%) underwent surgical resection of the abscess, and 31 (79.5%) received antimicrobial therapy alone. Median time to brain abscess resolution was 166 days for Nocardia and 356 days for fungal pathogens. Eleven of 39 patients (28.2%) died as a result of their brain abscess, including four of 24 patients (16%) with Nocardia and six of 10 patients (60%) with Aspergillus brain abscess. All‐cause mortality was 43.6%.Conclusion: Brain abscess remains an uncommon infectious complication following SOT. Nocardia and fungi accounted for 92% of pathogens in our cohort. Fungal brain abscess portends a poor prognosis. image
- 6 October 2023
- Published by BMJ in BMJ Case Reports
- Vol. 16 (10) , e256864
Rhodococcus erythropolis septic arthritis
A woman in her 50s presented with a 4-day history of left knee pain, erythema, swelling as well as malaise and rigours 1 month after undergoing a left knee meniscectomy. She was diagnosed with left native knee septic arthritis and underwent arthroscopic irrigation and debridement of the knee; cultures from synovial tissue grew Rhodococcus erythropolis. Rhodococcus spp are soil-dwelling and livestock-dwelling bacteria which occasionally cause disease in immunocompromised hosts. Infection in immunocompetent hosts is rare, and septic arthritis secondary to Rhodococcus erythropolis has not been reported previously.
- 6 October 2023
- Published by BMJ in BMJ Case Reports
- Vol. 16 (10) , e256864
Rhodococcus erythropolis septic arthritis
A woman in her 50s presented with a 4-day history of left knee pain, erythema, swelling as well as malaise and rigours 1 month after undergoing a left knee meniscectomy. She was diagnosed with left native knee septic arthritis and underwent arthroscopic irrigation and debridement of the knee; cultures from synovial tissue grew Rhodococcus erythropolis. Rhodococcus spp are soil-dwelling and livestock-dwelling bacteria which occasionally cause disease in immunocompromised hosts. Infection in immunocompetent hosts is rare, and septic arthritis secondary to Rhodococcus erythropolis has not been reported previously.
- Open Access
- 30 June 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (7) , 1077-1079
Facial skin lesions and diarrhea in a kidney transplant recipient
- 30 June 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (7) , 1077-1079
Open AccessFacial skin lesions and diarrhea in a kidney transplant recipient
- Open Access
- 3 September 2022
- Published by SAGE Publications in Journal of Investigative Medicine High Impact Case Reports
- Vol. 10
Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
Recurrent vulvovaginal candidiasis is a common disorder which causes significant morbidity among women worldwide, and treatment options are limited. Ibrexafungerp is a novel antifungal agent which was approved in 2021 for treatment of vulvovaginal candidiasis. We present a case of recurrent vulvovaginal candidiasis successfully treated with ibrexafungerp.
- 3 September 2022
- Published by SAGE Publications in Journal of Investigative Medicine High Impact Case Reports
- Vol. 10
Open AccessTreatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
Recurrent vulvovaginal candidiasis is a common disorder which causes significant morbidity among women worldwide, and treatment options are limited. Ibrexafungerp is a novel antifungal agent which was approved in 2021 for treatment of vulvovaginal candidiasis. We present a case of recurrent vulvovaginal candidiasis successfully treated with ibrexafungerp.
- 16 April 2021
- Published by BMJ in BMJ Case Reports
- Vol. 14 (4) , e241004
One man, three tick-borne illnesses
A 70-year-old man presented to the emergency department with fevers, ankle edema and nausea following a presumed insect bite on his ankle 1 month prior. On examination, he was febrile and had left leg pain with passive range of motion. Laboratory studies revealed anemia, thrombocytopenia, acute kidney injury and elevated aminotransaminases. Due to his recent travel to the Northeastern United States, he was suspected of having a possible tick-borne illness. Serologies were positive for Borrelia burgdorferi, Anaplasma phagocytophilum and Babesia microti, and the patient was diagnosed with Lyme disease, babesiosis and anaplasmosis. He was treated with doxycyline, atovaquone and azithromycin, leading to resolution of symptoms. While co-infection with Lyme disease is common, infection with three tickborne illnesses at one time is relatively rare.
- 16 April 2021
- Published by BMJ in BMJ Case Reports
- Vol. 14 (4) , e241004
One man, three tick-borne illnesses
A 70-year-old man presented to the emergency department with fevers, ankle edema and nausea following a presumed insect bite on his ankle 1 month prior. On examination, he was febrile and had left leg pain with passive range of motion. Laboratory studies revealed anemia, thrombocytopenia, acute kidney injury and elevated aminotransaminases. Due to his recent travel to the Northeastern United States, he was suspected of having a possible tick-borne illness. Serologies were positive for Borrelia burgdorferi, Anaplasma phagocytophilum and Babesia microti, and the patient was diagnosed with Lyme disease, babesiosis and anaplasmosis. He was treated with doxycyline, atovaquone and azithromycin, leading to resolution of symptoms. While co-infection with Lyme disease is common, infection with three tickborne illnesses at one time is relatively rare.